Abstract
Cerebral venous thrombosis (CVT) is an uncommon cerebrovascular disease, which has
been reported with covid infection as well as covid vaccines, particularly AstraZeneca
and Janssen vaccines. We present four consecutive cases of CVT after receiving either
Sinopharm or Sinovac vaccine, both of which are composed of an inactivated-virus.
All the patients recovered well with anticoagulation and discharged with a good functional
outcome. This is the first case series reporting CVT following the administration
of these vaccines.
Keywords
Abbreviations:
AZ (AstraZeneca vaccine), Covid (Coronavirus disease 2019), CVT (Cerebral venous thrombosis), EMA (European Medicine Agency), EUA (Emergency Use Authorization), mRS (modified Rankin scale), SARS-COV-2 (Severe Acute Respiratory Syndrome Cronavirus 2), WHO (World Health Organization)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Johns Hopkins University Coronavirus Resource Center. 14 October 2021; ([Online]Available from)
- 7 Vaccines Approved for Use by WHO. 14 October 2021; ([Online] Available from:)
- Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.Hum Vaccin Immunother. 2021; : 1-8https://doi.org/10.1080/21645515.2021.1981086
- AstraZeneca vaccine: timeline of what's happened since European countries suspended use of Covid jab. 14 October 2021; ([Online] Available from:) ([Accessed])
- FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review. 14 October 2021; ([Online] Available from:)
- Covid-19 vaccines and cerebral venous thrombosis.Pak J Neurol Sci (PJNS). 2021; 16: 3
- Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.Eur J Neurol. 2021; https://doi.org/10.1111/ene.15029
- Looking beyond COVID-19 vaccine phase 3 trials.Nat Med. 2021; 27: 205-211https://doi.org/10.1038/s41591-021-01230-y
- Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey.J Clin Med. 2021; 10: 2629https://doi.org/10.3390/jcm10122629
- Side effects and perceptions following Sinopharm COVID-19 vaccination.Int J Infect Dis. 2021; 111: 219-226https://doi.org/10.1016/j.ijid.2021.08.013
- Homocysteine, folate and vitamin B12 in puerperal cerebral venous thrombosis.J Neurol Sci. 2008; 272: 43-47https://doi.org/10.1016/j.jns.2008.03.021
- A study of hyperhomocysteinemia in cerebral venous sinus thrombosis.Indian J Med Res. 2020; 152: 584-594https://doi.org/10.4103/ijmr.IJMR_2125_18
- Cerebral venous thrombosis associated with COVID-19 infection: An observational, multicenter study.Cerebrovasc Dis Extra. 2021; 11: 55-60https://doi.org/10.1159/000516641
Article info
Publication history
Published online: January 13, 2022
Accepted:
December 25,
2021
Received in revised form:
December 7,
2021
Received:
October 19,
2021
Identification
DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106298
Copyright
© 2021 Elsevier Inc. All rights reserved.
